RT YZi Labs (@yzilabs)Easy Residency Season 2 is coming for founders in Web3, AI, and Biotech.Now with @BNBCHAIN’s MVB program under its wing.A global founder residency built for what’s next.The program kicks off October 6, 2025. ...

🌐 Autonomous Research Advances@Stanford runs a virtual lab of AI “scientists,” showing agent teams can co-design novel biotech solutions—signaling AI’s cross-industry upside.6/6 ...

Welcome to CNBC. com. I'm Frank Holland, anchor of Worldwide Exchange.We are tracking the action in the ETF market year to date. Net inflows are $678 billion according to Vetify. Uh, putting us on track for another record year.Joining me now to discuss the ETF market is Tom Stout, ARC Investment Management President and COO. Tom, thank you for joining us. >> Great to see you, Frank.Thanks for having me. >> All right. Um, so looking at the ETF uh action this week, what have you been seeing.And obviously mega ...

Company Overview - A biotech entrepreneur built a multibillion-dollar company at age 51 [1] Industry Recognition - Featured in ForbesOver50 [1]

Innovation Landscape - China has emerged as the second engine of innovation globally, although the US remains the leader in the field [1] - There's a substantial return of scientists to China from the US and the UK, driven by opportunities and capital investment [2] - The Chinese government facilitates the return of scientists by providing money and capital for investment [2] Talent Migration - Some scientists are reportedly leaving the United States due to policy concerns [1] - Scientists are moving to China because of opportunities to create companies, secure funding, and take risks [3] - Many scientists working with biotech companies in China are American-Chinese, frequently bridging the US and China [2][3] Competitive Advantage - China offers opportunities to create companies, be funded, and take risks, leading to success for many [3] - The US needs to maintain its leadership in innovation [3]

Company Overview - Scryb Inc. is proposing a consolidation of its common shares at a ratio of ten pre-consolidation shares for one post-consolidation share [1] - The company currently has 323,187,472 common shares issued and outstanding, which will reduce to approximately 32,318,747 shares post-consolidation [2] Consolidation Details - No fractional common shares will be issued; any resulting fractions will be rounded down to the nearest whole number without cash compensation [2] - A subsequent news release will provide the effective date of the consolidation, along with the new CUSIP and ISIN for the post-consolidation shares [3] - The post-consolidation shares will continue to trade under the existing name and trading symbol on the Canadian Securities Exchange (CSE) [3] Investment Focus - Scryb Inc. invests in and supports a portfolio of ventures across sectors such as AI, biotech, digital health, and cybersecurity [4]

Joining us now on set is Alli McCartney. She's managing director of UBS Private Wealth Management. You know what's so funny about market sentiment is literally yesterday it was like healthcare's dead.Yeah. Forget just forget it. You know, and and then today look at thermo look at some of these results and suddenly and now I feel like I've missed the trade.It's been one day, right. So that's where this market is, right. You have institutions that are pretty much resigned to staying where they are, seem to ha ...

The Unlikely Path From Iranian Revolution To Billionaire Biotech CEO https://t.co/StXw6OJNfC https://t.co/StXw6OJNfC ...

The Unlikely Path From Iranian Revolution To Billionaire Biotech CEO https://t.co/sgmOOyiGji https://t.co/sgmOOyiGji ...

China wants commercial insurance firms to invest in the development of homegrown medicines, Beijing’s latest bid to support its burgeoning biotech and pharmaceutical sector. https://t.co/OrbM2Dvm0Y ...